Sulodexide - Alfasigma
Alternative Names: 3GS; Glucoronylglucosaminoglycan sulphate; KRX-101; Sulodexide Gelcaps; Sulonex; Vessel; vessel due FLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Alfa Wassermann SpA
- Developer Alfa Wassermann SpA; Alfasigma; Keryx Biopharmaceuticals
- Class Antifibrotics; Antithrombotics; Glycosaminoglycans; Heparins; Urologics; Vascular disorder therapies
- Mechanism of Action Glycosaminoglycan stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Thrombosis; Vascular disorders
- Phase III Venous insufficiency
- Discontinued Diabetic nephropathies; Glomerulonephritis; Kidney disorders; Pulmonary fibrosis; Venous thromboembolism
Most Recent Events
- 28 Nov 2024 No development reported - Phase-III for Venous insufficiency in Czech Republic (PO)
- 28 Nov 2024 No development reported - Phase-III for Venous insufficiency in Slovakia (PO)
- 01 Aug 2023 Alfasigma terminates a phase-III SuloPrima trial in Venous insufficiency in Czech Republic (PO) (EudraCT2021-002311-64)